Adage Capital Partners Gp, L.L.C. Ultragenyx Pharmaceutical Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$51.6 Billion
Q1 2025

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,149,000 shares of RARE stock, worth $75.4 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

2,149,000

Previous 1,183,081 81.64%

Holding current value

$75.4 Million

Previous $49.8 Million 56.34%

% of portfolio

0.15%

Previous 0.09%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$36.21 - $45.78 $35 Million - $44.2 Million	965,919 Added 81.64%	2,149,000 $77.8 Million
Q4 2024 Feb 14, 2025	SELL	$42.07 - $57.72 $14.4 Million - $19.8 Million	-342,660 Reduced 22.46%	1,183,081 $49.8 Million
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $16.1 Million - $23.8 Million	400,741 Added 35.62%	1,525,741 $84.8 Million
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $36.5 Million - $50.3 Million	975,000 Added 650.0%	1,125,000 $46.2 Million
Q1 2024 May 15, 2024	SELL	$43.02 - $53.69 $37.6 Million - $47 Million	-875,000 Reduced 85.37%	150,000 $7 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $29.7 Million - $46 Million	935,000 Added 1038.89%	1,025,000 $49 Million
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $614,592 - $821,215	-17,600 Reduced 16.36%	90,000 $3.21 Million
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $537,840 - $750,960	-14,400 Reduced 11.8%	107,600 $4.96 Million
Q1 2023 May 15, 2023	SELL	$36.99 - $48.71 $665,820 - $876,780	-18,000 Reduced 12.86%	122,000 $4.89 Million
Q4 2022 Feb 14, 2023	SELL	$33.72 - $46.33 $507,890 - $697,822	-15,062 Reduced 9.71%	140,000 $6.49 Million
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $21 Million - $34.7 Million	-524,938 Reduced 77.2%	155,062 $6.42 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $916,000 - $1.71 Million	-20,000 Reduced 2.86%	680,000 $40.6 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $5.9 Million - $7.03 Million	80,000 Added 12.9%	700,000 $58.9 Million
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $28.1 Million - $36.9 Million	360,000 Added 138.46%	620,000 $55.9 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $6.91 Million - $8.68 Million	75,000 Added 40.54%	260,000 $24.8 Million
Q1 2021 May 17, 2021	BUY	$106.9 - $167.73 $2.08 Million - $3.27 Million	19,500 Added 11.78%	185,000 $21.1 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $14 Million - $29.4 Million	165,500 New	165,500 $22.9 Million
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $1.73 Million - $3.44 Million	-44,476 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$71.81 - $90.15 $20.3 Million - $25.5 Million	-283,024 Reduced 86.42%	44,476 $3.4 Million
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $7.85 Million - $13.8 Million	-161,703 Reduced 33.05%	327,500 $25.2 Million
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $16.9 Million - $22.3 Million	381,703 Added 355.07%	489,203 $24.9 Million
Q4 2017 Feb 14, 2018	SELL	$43.54 - $57.32 $3.53 Million - $4.64 Million	-81,000 Reduced 42.97%	107,500 $4.99 Million
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $9.39 Million - $12.5 Million	188,500	188,500 $10 Million

Others Institutions Holding RARE

# of Institutions

336

Shares Held

88.9M

Call Options Held

1.08M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.46B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Ultragenyx Pharmaceutical Inc. Transaction History